Retreatment management strategies when first-line tuberculosis therapy fails

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 4, 2005, Pages 421-429

  Saravia, J C ^a   Appleton, S C ^b,c   Rich, M L ^b,d   Sarria, M ^a   Bayona, J ^b,c,d   Becerra, Mercedes C ^b,c,d  

^a Natl Tuberculosis Control Program   (Peru)

^b Socios Salud Suc Peru/Ptnrs Hlth   (Peru)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Category I regimen; Category II; DOTS Plus; Multidrug resistant tuberculosis; Treatment failure

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PERU; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 17144386948     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. World Health Organization. WHO Report 2002: Global Tuberculosis Control. WHO/CDS/TB/2002.29. Geneva, Switzerland: WHO, 2002.
2. World Health Organization. WHO Report on the Tuberculosis Epidemic. WHO/TB/97.224. Geneva, Switzerland: WHO, 1997.
3. Ministerio de Salud. Tuberculosis en el Peru: Informe 2000. Lima, Perú: Dirección General de Salud de las Personas, Programa Nacional de Control de Enfermedades Transmisibles-Control de la Tuberculosis, 2000.
4. World Health Organization. Treatment of Tuberculosis, Guidelines for National TB Programmes. WHO/TB/97.220. Geneva, Switzerland: WHO, 1997.
5. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug resistant tuberculosis: treatment outcomes in six countries. JAMA 2000; 283: 2537-2545.
6. World Health Organization. Treatment of Tuberculosis. Guidelines for National TB Programmes. 3rd ed. WHO/CDS/TB/2003.313. Geneva, Switzerland: WHO, 2003.
7. Jave O, Castilla T, Prado A, Asto T. Drug susceptibility testing to antituberculous drugs in new patients who fail Category I regimen 2RHZE/4R2H2. Guayaquil, Ecuador: IUATED Eatin American Region Conference, 24-27 October 2000. [Poster presentation]
8. Chávez-Pachas A M, Blank R, Smith-Fawzi M C, Bayona J, Becerra M C, Mitnick C D. Identifying early treatment failure on Category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004; 8: 52-58.
9. Quy H T W, Lan N T N, Bordgorff M W, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard retreatment regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-636.
10. Ministerio de Salud. Actualización de la doctrina, normas y procedimientos para el control de la tuberculosis en el Peru. Lima, Peru: Dirección General de Salud de las Personas, Ministerio de Salud, 2001.
11. National Tuberculosis Program, Ministry of Health. Directiva No. 006-96-PCT: 'Uso racional de los esquemas de tratamiento diferenciado en tuberculosis', April 17, 1996. Lima, Peru: Dirección General de Salud de las Personas, Ministerio de Salud, 1996.
12. Suarez P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
13. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
14. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481.
15. Canetti G, Rist N, Grosset J. Mésure de la sensibilité du bacille tuberculeux aux drogues antibacillaires pour la méthode des proportions. Rev Tuberc (Paris) 1963; 27: 217-272.
16. Centro Panamericano de Zoonosis. Manual de normas y procedimientos técnicos para la bacteriología de la tuberculosis. Buenos Aires, Argentina: CEPANZO/OPS/OMS; 1988.
17. Wayne L G. Simple pyrazinamide and urease test for routine identification of mycobacteria. Am Rev Resp Dis 1974; 109: 147-151.
18. Tahaoglu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
19. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
20. Manalo F, Tan F, Sbarbaro J A, Iseman M D. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis 1990; 142: 1301-1305.
21. Kimerling M E, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO retreatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999; 3: 451-453.
22. Centers for Disease Control and Prevention. Primary multidrug-resistant tuberculosis-Ivanovo Oblast, Russia, 1999. MMWR 1999; 48: 661-663.
23. Coninx R, Mathieu C, Debacker M, et al. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet 1999; 353: 969-973.
24. Lan N T N, Iademarco M F, Binkin N J, Tung L B, Quy H T, Cô N V. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2001; 5: 575-578.
25. Heldal E, Arnadottir T, Cruz J R, Tardencilla A, Chacon L. Low failure rate in standardized retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of 'chronic' patients. Int J Tuberc Lung Dis 2001; 5: 129-136.
26. Kim J Y, Mukherjee J S, Rich M L, Mate K, Bayona J, Becerra M C. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis 2003; 83: 59-65.
27. Gupta R, Cegielski J P, Espinal M A, et al. Increasing transparency in partnerships for health-introducing the Green Light Committee. Trop Med Int Health 2002; 7: 970-976.
28. Rieder H. Recommendations for the control and treatment of tuberculosis. Paris, France: International Union Against Tuberculosis and Lung Disease, 2002.
29. Farmer P E, Bayona J, Becerra M C, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
30. Furin J J, Becerra M C, Shin S S, Kim J Y, Bayona J, Farmer P E. Effect of short-course, empiric regimens in individuals infected with drug-resistant Mycobacterium tuberculosis strains. Eur J Clin Microbiol Infect Dis 2000; 19: 132-136.
31. Bureau of Tuberculosis Control. Clinical Policies and Protocols. 3rd ed. New York, NY: New York City Department of Health, 1999.